Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • Blog
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • Blog
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. RNA research
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

RNA research

[0171-G898-20] miRNA All-In-One cDNA Synthesis Test - 20 rxn
miRNA All-In-One cDNA Synthesis Test - 20 rxn
439.00 € 439.0 EUR
[0171-G898-100] miRNA All-In-One cDNA Synthesis Test - 100 rxn
miRNA All-In-One cDNA Synthesis Test - 100 rxn
1,053.25 € 1053.25 EUR
[0813-MR201] miRNA 1st Strand cDNA Synthesis Test (by tailing A)
miRNA 1st Strand cDNA Synthesis Test (by tailing A)
200.00 € 200.0 EUR
[0813-MR101] miRNA 1st Strand cDNA Synthesis Test (by stem-loop), 50rxn
miRNA 1st Strand cDNA Synthesis Test (by stem-loop), 50rxn
116.00 € 116.0 EUR
[0322-MR800A-2] mRNAExpress RFP transcript - 20 ug.
mRNAExpress RFP transcript - 20 ug.
1,200.00 € 1200.0 EUR
[0743-RNTK-002] mRNA in vivo delivery Test - Reagent Size 1 ml, Buffer 60 ml
mRNA in vivo delivery Test - Reagent Size 1 ml, Buffer 60 ml
7,875.00 € 7875.0 EUR
[1015-10614ES84] mRNA Vaccinia Capping Enzyme GMP-grade (10 U/μL) - 2 KU
mRNA Vaccinia Capping Enzyme GMP-grade (10 U/μL) - 2 KU
338.15 € 338.15000000000003 EUR
[1015-10614ES96] mRNA Vaccinia Capping Enzyme GMP-grade (10 U/μL) - 100 KU
mRNA Vaccinia Capping Enzyme GMP-grade (10 U/μL) - 100 KU
9,531.75 € 9531.75 EUR
[1015-10612ES92] mRNA Cap 2´-O-Methyltransferase GMP-grade (50 U/μl) - 10000 U
mRNA Cap 2´-O-Methyltransferase GMP-grade (50 U/μl) - 10000 U
195.15 € 195.15 EUR
[0171-MNH02105] hsa-miR-381-3p miRNA Antagomir
hsa-miR-381-3p miRNA Antagomir
545.00 € 545.0 EUR
[0171-MNH01506] hsa-miR-203 miRNA Antagomir
hsa-miR-203 miRNA Antagomir
545.00 € 545.0 EUR
[0171-MCH01052] hsa-miR-10b-3p miRNA Mimic
hsa-miR-10b-3p miRNA Mimic
425.00 € 425.0 EUR
[1012-HBP003801] dsRNA ELISA Test - 96 wells plate
dsRNA ELISA Test - 96 wells plate
1,240.00 € 1240.0 EUR
[0220-RNT-SCI-10080100] dsRNA 142 bp (Positive control for dsRNA detection by Anti-dsRNA monoclonal J2, K1 und K2 antibodies) - 50ug.
dsRNA 142 bp (Positive control for dsRNA detection by Anti-dsRNA monoclonal J2, K1 und K2 antibodies) - 50ug.
408.00 € 408.0 EUR
[0062-YSR-300] Yeast Total RNA - 0.025mG.
Yeast Total RNA - 0.025mG.
659.00 € 659.0 EUR
[0743-NKR-T001] Virus RNA pure Test 50T
Virus RNA pure Test 50T
1,242.00 € 1242.0 EUR
[0813-RC323-01] Viral DNA/RNA extraction Mini Test Pro - 50 reactions
Viral DNA/RNA extraction Mini Test Pro - 50 reactions
274.00 € 274.0 EUR
[0036-R4334566] Universal RNA - Mouse Normal Tissues-4x100 µg
Universal RNA - Mouse Normal Tissues-4x100 µg
1,790.00 € 1790.0 EUR
[0171-MPH00000] Universal 3' miRNA Reverse Primer -150 μl / 10 μM
Universal 3' miRNA Reverse Primer -150 μl / 10 μM
284.00 € 284.0 EUR
[1044-AT351-01] TransScript® miRNA First-Strand cDNA Synthesis SuperMix; 20 rxns×20 µl  system
TransScript® miRNA First-Strand cDNA Synthesis SuperMix; 20 rxns×20 µl system
649.50 € 649.5 EUR
  • 6
  • 7
  • 8
  • 9
  • 10

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)